PCN91 BEVACIZUMAB + PACLITAXEL + CARBOPLATIN (BEV + PAC + CAR) VS. PEMETREXED + CISPLATIN (PEM + CIS) IN ADENOCARCINOMA NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A COST-EFFECTIVENESS ANALYSIS FROM A POLISH PUBLIC PAYER'S PERSPECTIVE
P Kawalec, P Badurak, T Denisso, D Jastrzebski, M Marek, A Pluzanski, A Szczesna, M Szkultecka-Debek, M Russel-SzymczykVolume:
13
Year:
2010
Language:
english
DOI:
10.1016/s1098-3015(11)71986-6
File:
PDF, 77 KB
english, 2010